Teva, Biolojic in pact for developing therapeutic antibodies for inflamation

Teva Pharmaceutical and Biolojic Design or Biolojic, “a biotechnology company that uses computational biology and artificial intelligence to transform antibodies into intelligent medicinal solutions” announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma. BD9 is a dual specific antibody that can block both TSLP and IL-13, and has the potential to deliver treatment across typically TH2-driven inflammatory diseases, such as atopic dermatitis and asthma. Existing drugs currently approved by health authorities focus on only one of these two drivers of inflammation, and do not respond to pathway dynamics. When TSLP or IL13 is upregulated BD9 can bind to either target with both arms and with high affinity, therefore having the potential to help more patients and improve outcomes. This agreement supports one of Teva‘s key pillars in its Pivot to Growth strategy announced in May 2023, to step up innovation, by enhancing the Company’s early-stage pipeline organically and through strategic partnerships…Under the terms of the agreement, Teva will receive exclusive rights to develop, manufacture and commercialize BD9 worldwide. In exchange, Biolojic will receive an upfront payment, and will be eligible to receive subsequent milestone payments over the next several years, based on the achievement of certain pre-clinical, clinical, regulatory, and commercial milestones. Biolojic is also eligible to receive tiered royalties in the mid-single to low-double digit on product sales should Teva successfully commercialize a therapy